Pliant Therapeutics, Inc. (PLRX)

Market Cap	843.26M
Revenue (ttm)	1.58M
Net Income (ttm)	-161.34M
Shares Out	60.32M
EPS (ttm)	-2.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	302,696
Open	13.80
Previous Close	13.25
Day's Range	13.58 - 14.09
52-Week Range	11.21 - 24.74
Beta	1.13
Analysts	Strong Buy
Price Target	50.14 (+258.66%)
Earnings Date	May 14, 2024

About PLRX

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 3, 2020
• Employees: 158
• Stock Exchange: NASDAQ
• Ticker Symbol: PLRX

Financial Performance

In 2023, PLRX's revenue was $1.58 million, a decrease of -83.69% compared to the previous year's $9.69 million. Losses were -$161.34 million, 30.8% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for PLRX stock is "Strong Buy." The 12-month stock price forecast is $50.14, which is an increase of 258.66% from the latest price.

Price Target

$50.14

(258.66% upside)

Analyst Consensus: Strong Buy